Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Latent Mastocytosis Triggered by COVID-19 Vaccination: A Case Report

Author(s): Gianfranco Calogiuri*, Caterina Foti, Maurizio Congedo, Eustachio Nettis, Luigi Paladini, Giuseppina Greco, Vincenzo Pavone and Angelo Vacca

Volume 24, Issue 4, 2024

Published on: 10 October, 2023

Page: [495 - 498] Pages: 4

DOI: 10.2174/0118715303241179230927105454

Price: $65

Abstract

Background: Hereby, we describe the first case of latent mastocytosis triggered by mRNA-based vaccine to prevent COVID-19 infection.

Case Presentation: In a 42-year-old Arabian man affected by slight, undiagnosed mastocytosis, the second dose of the COVID-19 vaccine made more blatant his latent disease. The postvaccination diagnostic iter is illustrated and the potential reasons causing the onset of the cutaneous mastocytosis are discussed.

Conclusion: Clinicians should keep a longer follow-up of their patients after the COVID-19 vaccination, not related to few hours, for the risk of immediate-type adverse events only.

« Previous
Graphical Abstract

[1]
Darmarajan, T.; Paudel, K.R.; Candasamy, M.; Chellian, J.; Madheswaran, T.; Sakthivel, L.P.; Goh, B.H.; Gupta, P.K.; Jha, N.K.; Devkota, H.P.; Gupta, G.; Gulati, M.; Singh, S.K.; Hansbro, P.M.; Oliver, B.G.G.; Dua, K.; Chellappan, D.K. Autoantibodies and autoimmune disorders in SARS-CoV-2 infection: Pathogenicity and immune regulation. Environ. Sci. Pollut. Res. Int., 2022, 29(36), 54072-54087.
[http://dx.doi.org/10.1007/s11356-022-20984-7] [PMID: 35657545]
[2]
Chen, Y.; Xu, Z.; Wang, P.; Li, X.M.; Shuai, Z.W.; Ye, D.Q.; Pan, H.F. New‐onset autoimmune phenomena post‐COVID‐19 vaccination. Immunology, 2022, 165(4), 386-401.
[http://dx.doi.org/10.1111/imm.13443] [PMID: 34957554]
[3]
Carter, M.C.; Metcalfe, D.D.; Komarow, H.D. Mastocytosis. Immunol. Allergy Clin. North Am., 2014, 34(1), 181-196.
[http://dx.doi.org/10.1016/j.iac.2013.09.001] [PMID: 24262698]
[4]
Hartmann, K.; Escribano, L.; Grattan, C.; Brockow, K.; Carter, M.C.; Alvarez-Twose, I.; Matito, A.; Broesby-Olsen, S.; Siebenhaar, F.; Lange, M.; Niedoszytko, M.; Castells, M.; Oude Elberink, J.N.G.; Bonadonna, P.; Zanotti, R.; Hornick, J.L.; Torrelo, A.; Grabbe, J.; Rabenhorst, A.; Nedoszytko, B.; Butterfield, J.H.; Gotlib, J.; Reiter, A.; Radia, D.; Hermine, O.; Sotlar, K.; George, T.I.; Kristensen, T.K.; Kluin-Nelemans, H.C.; Yavuz, S.; Hägglund, H.; Sperr, W.R.; Schwartz, L.B.; Triggiani, M.; Maurer, M.; Nilsson, G.; Horny, H.P.; Arock, M.; Orfao, A.; Metcalfe, D.D.; Akin, C.; Valent, P. Cutaneous manifestations in patients with mastocytosis: consensus report of the european competence network on mastocytosis; the american academy of allergy, asthma & immunology; and the european academy of allergology and clinical immunology. J. Allergy Clin. Immunol., 2016, 137(1), 35-45.
[http://dx.doi.org/10.1016/j.jaci.2015.08.034] [PMID: 26476479]
[5]
Berezowska, S.; Flaig, M.J.; Ruëff, F.; Walz, C.; Haferlach, T.; Krokowski, M.; Kerler, R.; Petat-Dutter, K.; Horny, H.P.; Sotlar, K. Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis. Mod. Pathol., 2014, 27(1), 19-29.
[http://dx.doi.org/10.1038/modpathol.2013.117] [PMID: 23807778]
[6]
Bonadonna, P.; Brockow, K.; Niedoszytko, M.; Elberink, H.O.; Akin, C.; Nedoszytko, B. COVID-19 vaccination in mastocytosis: Recommendations of the European CompetenceNetwork on Mastocytosis (ECNM) and American Initiative in Mast cell diseases (AIM). JACI In Pract, 2022, 9, 2139-2144.
[7]
Kaakati, R.; Khokhar, D.; Akin, C. Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome. J. Allergy Clin. Immunol. Pract., 2021, 9(8), 3198-3199.
[http://dx.doi.org/10.1016/j.jaip.2021.05.010] [PMID: 34033981]
[8]
Tuncay, G.; Bostan, O.C.; Damadoglu, E.; Karakaya, G.; Kalyoncu, A.F. SARS-CoV-2 vaccines are well tolerated in patients with mastocytosis. Ann. Allergy Asthma Immunol., 2022, 128(6), 733-734.
[http://dx.doi.org/10.1016/j.anai.2022.02.026] [PMID: 35257871]
[9]
Lazarinis, N.; Bossios, A.; Gülen, T. COVID-19 vaccination in the setting of mastocytosis—Pfizer-BioNTech mRNA vaccine is safe and well tolerated. J. Allergy Clin. Immunol. Pract., 2022, 10(5), 1377-1379.
[http://dx.doi.org/10.1016/j.jaip.2022.01.037] [PMID: 35123098]
[10]
Ruano-Zaragoza, M.; Carpio-Escalona, L.V.; Diaz-Beya, M.; Piris-Villaespesa, M.; Castaño-Diez, S.; Muñoz-Cano, R.; González-de-Olano, D. Safety of COVID-19 vaccination in patients with clonal mast cell disorders. J. Allergy Clin. Immunol. Pract., 2022, 10(5), 1374-1376.e3.
[http://dx.doi.org/10.1016/j.jaip.2022.01.030] [PMID: 35121156]
[11]
Knight, J.S.; Caricchio, R.; Casanova, J.L.; Combes, A.J.; Diamond, B.; Fox, S.E.; Hanauer, D.A.; James, J.A.; Kanthi, Y.; Ladd, V.; Mehta, P.; Ring, A.M.; Sanz, I.; Selmi, C.; Tracy, R.P.; Utz, P.J.; Wagner, C.A.; Wang, J.Y.; McCune, W.J. The intersection of COVID-19 and autoimmunity. J. Clin. Invest., 2021, 131(24), e154886.
[http://dx.doi.org/10.1172/JCI154886] [PMID: 34710063]
[12]
Wechsler, J.B.; Butuci, M.; Wong, A.; Kamboj, A.P.; Youngblood, B.A. Mast cell activation is associated with post‐acute COVID‐19 syndrome. Allergy, 2022, 77(4), 1288-1291.
[http://dx.doi.org/10.1111/all.15188] [PMID: 34820848]
[13]
Butterfield, J.H. Response of severe systemic mastocytosis to interferon alpha. Br. J. Dermatol., 1998, 138(3), 489-495.
[http://dx.doi.org/10.1046/j.1365-2133.1998.02131.x] [PMID: 9580806]
[14]
Sachinidis, A.; Garyfallos, A. COVID‐19 vaccination can occasionally trigger autoimmune phenomena, probably via inducing age‐associated B cells. Int. J. Rheum. Dis., 2022, 25(1), 83-85.
[http://dx.doi.org/10.1111/1756-185X.14238] [PMID: 34766739]
[15]
Sousa, L.G.; McGrail, D.J.; Li, K.; Marques-Piubelli, M.L.; Gonzalez, C.; Dai, H.; Ferri-Borgogno, S.; Godoy, M.; Burks, J.; Lin, S.Y.; Bell, D.; Ferrarotto, R. Spontaneous tumor regression following COVID-19 vaccination. J. Immunother. Cancer, 2022, 10(3), e004371.
[http://dx.doi.org/10.1136/jitc-2021-004371] [PMID: 35241495]
[16]
McMahon, D.E.; Amerson, E.; Rosenbach, M.; Lipoff, J.B.; Moustafa, D.; Tyagi, A.; Desai, S.R.; French, L.E.; Lim, H.W.; Thiers, B.H.; Hruza, G.J.; Blumenthal, K.G.; Fox, L.P.; Freeman, E.E. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J. Am. Acad. Dermatol., 2021, 85(1), 46-55.
[http://dx.doi.org/10.1016/j.jaad.2021.03.092] [PMID: 33838206]
[17]
Català, A.; Muñoz-Santos, C.; Galván-Casas, C.; Roncero Riesco, M.; Revilla Nebreda, D.; Solá-Truyols, A.; Giavedoni, P.; Llamas-Velasco, M.; González-Cruz, C.; Cubiró, X.; Ruíz-Villaverde, R.; Gómez-Armayones, S.; Gil Mateo, M.P.; Pesqué, D.; Marcantonio, O.; Fernández-Nieto, D.; Romaní, J.; Iglesias, P. N.; Carnero G, L.; Tercedor-Sanchez, J.; Carretero, G.; Masat-Ticó, T.; Rodríguez-Jiménez, P.; Gimenez-Arnau, A.M.; Utrera-Busquets, M.; Vargas L, E.; Angulo M, A.G.; San Juan Lasser, E.; Iglesias-Sancho, M.; Alonso N, L.; Hiltun, I.; Cutillas M, E.; Polimon O, I.; Marinero E, S.; García-Navarro, X.; Calderón Gutiérrez, M.J.; Baeza-Hernández, G.; Bou Camps, L.; Toledo-Pastrana, T.; Guilabert, A. Cutaneous reactions after SARS-CoV-2 vaccination: A cross-sectional Spanish nationwide study of 405 cases. Br. J. Dermatol., 2022, 186(1), 142-152.
[http://dx.doi.org/10.1111/bjd.20639] [PMID: 34254291]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy